Global TCV Vaccines Market, by Vaccine Brand (Ty21a (Vivotif), ViCPS (Typhim Vi), Vi-TT (Peda-typhTM), and Typbar TCV), by Distribution Channel (Public (UNICEF and Tender (Govt.)) and Private), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 332.6 million in 2022, and is expected to exhibit a CAGR of 12.1% over the forecast period (2022-2030), as highlighted in a new report published by Coherent Market Insights.
Efficient antibiotic treatment can reduce the fatality rate of typhoid to less than 1%. However, recent past has witnessed an increase in antimicrobial resistance of Salmonella Typhi, which is expected to drive the market growth over the forecast period.
For instance, according to the Typhoid Vaccine Acceleration Consortium (TyVAC), which is a partnership between University of Maryland School of Medicine, University of Oxford, and PATH, by 2014, 97% of registered typhoid cases in Malawi resisted treatment from multiple antibiotics. Moreover, as per the same source, the antibiotic resistant typhoid cases are increasing, globally. In relation to this, in 2015, the World Health Assembly (WHA) started a global action plan to tackle drug resistance, which focuses on prevention, surveillance, and research.
Furthermore, the Wellcome Trust and current surveillance projects, including Surveillance for Enteric Fever in Asia Project (SEAP) and Severe Typhoid Fever Surveillance in Africa (SETA), are conducting research to identify typhoid drug-resistance trends and monitor antibiotic use across South Asia and Sub-Saharan Africa.
This is expected to shift the attention towards disease prevention rather than cure, which in turn will have positive impact on increasing immunization efforts. This, along with all the other drivers (disease prevalence, increasing government support, initiatives, and product launches) is expected to support growth of the market over the forecast period.
Global TCV Vaccines Market – Impact of Coronavirus (COVID-19) Pandemic
The symptoms of COVID-19, it is often confused with regular cough, cold, flu and in some cases, even typhoid. While there is no direct relation between COVID-19 and typhoid infection, in some cases of COVID-19 infection, typhoid also comes positive and one needs to get further tests done to get confirmation. The bacteria causing typhoid also enters the bloodstream. Hence chances of typhoid infection is expected in a person infected with COVID-19. Moreover, COVID-19 weakens the body’s defence mechanism making it prone to other infections and diseases, including typhoid. Thus there is very less impact of COVID-19 on the TCV vaccines market.
Browse 24 Market Data Tables and 22 Figures spread through 167 Pages and in-depth TOC on “TCV Vaccines Market”- Global Forecast to 2030, by Vaccine Brand (Ty21a (Vivotif), ViCPS (Typhim Vi), Vi-TT (Peda-typhTM), and Typbar TCV), by Distribution Channel (Public (UNICEF and Tender (Govt.)) and Private), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa),
To know the latest trends and insights prevalent in the global TCV vaccines market, click the link below:
https://www.coherentmarketinsights.com/market-insight/tcv-vaccines-market-4936
Increasing research and development activities for development of typhoid vaccines for treating young children is expected to drive the market growth and provide opportunity for key players to launch their products in the global market. Currently, there is only one typhoid conjugate vaccine (Typbar TCV) that has been prequalified by WHO to treat young children below two years of age. Typhoid conjugate vaccine (TCV) is more effective at preventing the disease than other available vaccines.
For instance, in 2018, Prokarium Limited, a U.K.-based vaccine developer, secured US$ 10 million in funding from various Saudi, Swedish, and Korean investors for the development of new ground breaking vaccines against enteric fever including typhoid.
Key Takeaways of the Global TCV Vaccines Market:
- The global TCV vaccines market is expected to exhibit a CAGR of 12.1% over the forecast period, owing to increasing adoption of inorganic growth strategies by key players operating in the market. For instance, Emergent BioSolutions, Inc. acquired PaxVax, Inc. in 2018. Emergent BioSolutions gained access to Vivotif and Vaxchora, which are both U.S. FDA-licensed vaccines.
- Among vaccine brand, ViCPS (Typhim Vi) segment accounted for largest market share in 2021, owing to advantages offered by this vaccine such as application in children ≥ two years of age (six years for live attenuated vaccine) and increased efficacy.
- Key players operating in the global TCV vaccines market include GlaxoSmithKline PLC, Sanofi SA, Bharat Biotech, PT BIO FARMA, and PaxVax, Inc.
